ADC Development for Gastrointestinal Stromal Tumors (GIST)

Antibody-drug conjugates (ADCs) show significant therapeutic promise for cancer, which are designed to combine the specificity of antibodies directed against tumor-associated targets with potent cytotoxic drugs. Creative Biolabs is one of the world’s leading and most-trusted providers in the ADC design and production. We provide a full range of ADCs development services targeting the gastrointestinal stromal tumors (GIST). Our services include ADCs development, small scale production, and superior scale up for commercial supply.

Introduction of GIST

GISTs are the most common mesenchymal tumors of the gastrointestinal tract (GIT), which arise from precursor cells and thought to be related to the interstitial cells of Cajal. The interstitial cells of Cajal mainly exist in the myenteric plexus that comprising a network similar to fibroblasts and smooth muscle cells, which play a role in regulating gut motor functions such as peristalsis. GISTs can occur in different parts of GI tract, from esophagus to anus, as well as within the omentum, mesentery, and retroperitoneum. Symptoms of GIST include anemia, abdominal pain, a mass in the abdomen, nausea, vomiting, loss of appetite, weight loss and difficulty swallowing. GISTs can specifically express KIT protein (CD117), which is a type of transmembrane receptor with tyrosine kinase activity. The protein is considered as a marker to distinguish GISTs from other stromal or mesenchymal tumors. Surgery and targeted drug therapy are the common treatment for the cancer currently.

Gastrointestinal stromal tumors (GIST). Fig.1 Gastrointestinal stromal tumors (GIST).

ADC Development for GIST

Targeted drug therapy represents one of the main treatment approaches for the GISTs. ADCs is a novel targeted drug therapy that is investigated actively targeting the cancer. c-KIT protein is highly expressed in GIST cell and has been selected as a target used in the ADCs design. An anti-c-KIT ADC, LOP628, has been developed to improve the anti-cancer outcome. LOP628 consists of a humanized anti-c-KIT antibody-LMJ729 conjugated to the microtubule destabilizing maytansinoid, DM1, via a noncleavable linker (SMCC). Preclinical trial results showed that LOP628 performed a potent antiproliferative activity on c-KIT-positive cell lines. Thus, the c-KIT-directed ADC may be a promising therapeutic option for the treatment of mutant and c-KIT-positive GIST cancers.

ADCs for the targeted delivery of chemotherapy to cancer cells. Fig.2 ADCs for the targeted delivery of chemotherapy to cancer cells.

What Can We Do for You?

Conventional cancer treatment options such as the chemotherapy or radiation therapy can lead to resistance. Whereas, ADCs take advantage of antigen specificity of monoclonal antibodies to deliver cytotoxic drugs selectively to antigen-expressing tumor cells, which are believed to be a new and effective therapeutic option for cancer patients. Backed by a strong reputation for leading development capabilities and quality control, Creative Biolabs provides customized ADCs construction services for the GIST treatment.The target of our ADC development for GIST include but not limited to:

cKIT  

If you are interested in our service, please do not hesitate to contact us for more details.


For lab research use only, not for any in vivo human use.



Related Sections

Disease Research:
Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828
 Email:

Inquiry

Top